Work

Targeting Topoisomerase 1 to inhibit Hypoxia Inducible Factor 1

Year: 2004

Type: article

Abstract: HIF-1 is a key factor in cancer progression. Efforts are underway to identify and develop small molecules that inhibit HIF-1 transcriptional activity. What are the best targets and the best ways to develop HIF-1 inhibitors are open questions. However, several “non-selective” HIF-1 inhibitors have been identified, which are either in the clinic or under development. In this article, we discuss how topoisomerase 1 poisons, which inhibit HIF-1a protein accumulation and transcriptional activity, can be “rationally” used to target HIF-1 for cancer therapy.

Source: Cell Cycle

DOI: 10.4161/cc.3.2.688

Authors: Annamaria Rapisarda, Robert H. Shoemaker, Giovanni Melillo

Institutions: Leidos (United States), Science Applications International Corporation (United States), Frederick National Laboratory for Cancer Research, National Cancer Institute

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute